Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

BioMarin to acquire Alesta Therapeutics for $275 million

PUBLIC · BMRNAug 18, 2026•about 3 hours ago

Acquiring Company

BioMarin Pharmaceutical

Acquired Company

Alesta Therapeutics

San RafaelBiotechnologyBiotechnologyHealth CareTherapeutics

Description

BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. This acquisition aims to bring Alesta's promising product, ALE1, to market as a potential first oral therapy for hypophosphatasia. The transaction is expected to close this quarter, following customary conditions.

Company Information

Company

BioMarin Pharmaceutical

Location

San Rafael, California, United States

About

BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

Don't miss BioMarin Pharmaceutical's next move

Get an email the moment BioMarin Pharmaceutical makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for BioMarin Pharmaceutical's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Alesta Therapeutics?

Alesta Therapeutics was acquired by BioMarin Pharmaceutical, based in San Rafael. The deal was reported on August 18, 2026. BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. BioMarin Pharmaceutical is publicly traded (BMRN) and operates in Biotechnology.

When did BioMarin Pharmaceutical acquire Alesta Therapeutics?

BioMarin Pharmaceutical's acquisition of Alesta Therapeutics was reported on August 18, 2026. BioMarin Pharmaceutical Inc. has announced its agreement to acquire Alesta Therapeutics for $275 million upfront, with additional payments based on milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Alesta Therapeutics do?

Alesta Therapeutics is a biotechnology company focused on developing therapies for rare genetic diseases. The company is engaged in advancing innovative treatments and conducting clinical trials to find effective solutions for serious health conditions. It is privately held, operating in Biotechnology.